Jianliang Xu,Kai Xu,Seolkyoung Jung,Andrea Conte,Jenna Lieberman,Frauke Muecksch,Julio Cesar Cetrulo Lorenzi,Solji Park,Fabian Schmidt,Zijun Wang,Yaoxing Huang,Yang Luo,Manoj S. Nair,Pengfei Wang,Jonathan E. Schulz,Lino Tessarollo,Tatsiana Bylund,Gwo-Yu Chuang,Adam S. Olia,Tyler Stephens,I-Ting Teng,Yaroslav Tsybovsky,Tongqing Zhou,Vincent Munster,David D. Ho,Theodora Hatziioannou,Paul D. Bieniasz,Michel C. Nussenzweig,Peter D. Kwong,Rafael Casellas

Abstract:Abstract Since the start of the COVID-19 pandemic, SARS-CoV-2 has caused millions of deaths worldwide. Although a number of vaccines have been deployed, the continual evolution of the receptor-binding domain (RBD) of the virus has challenged their efficacy. In particular, the emerging variants B.1.1.7, B.1.351 and P.1 (first detected in the UK, South Africa and Brazil, respectively) have compromised the efficacy of sera from patients who have recovered from COVID-19 and immunotherapies that have received emergency use authorization 1–3 . One potential alternative to avert viral escape is the use of camelid VHHs (variable heavy chain domains of heavy chain antibody (also known as nanobodies)), which can recognize epitopes that are often inaccessible to conventional antibodies 4 . Here, we isolate anti-RBD nanobodies from llamas and from mice that we engineered to produce VHHs cloned from alpacas, dromedaries and Bactrian camels. We identified two groups of highly neutralizing nanobodies. Group 1 circumvents antigenic drift by recognizing an RBD region that is highly conserved in coronaviruses but rarely targeted by human antibodies. Group 2 is almost exclusively focused to the RBD–ACE2 interface and does not neutralize SARS-CoV-2 variants that carry E484K or N501Y substitutions. However, nanobodies in group 2 retain full neutralization activity against these variants when expressed as homotrimers, and—to our knowledge—rival the most potent antibodies against SARS-CoV-2 that have been produced to date. These findings suggest that multivalent nanobodies overcome SARS-CoV-2 mutations through two separate mechanisms: enhanced avidity for the ACE2-binding domain and recognition of conserved epitopes that are largely inaccessible to human antibodies. Therefore, although new SARS-CoV-2 mutants will continue to emerge, nanobodies represent promising tools to prevent COVID-19 mortality when vaccines are compromised.

Potent Neutralization of SARS-CoV-2 by Hetero-Bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain

A potent neutralizing nanobody targeting a unique epitope on the receptor-binding domain of SARS-CoV-2 spike protein

A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants

A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration

Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants

Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein

A Novel Nanobody Broadly Neutralizes SARS‐CoV‐2 Via Induction of Spike Trimer Dimers Conformation

Development of Broad-Spectrum Nanobodies for the Therapy and Diagnosis of SARS-CoV-2 and Its Multiple Variants

Super broad and protective nanobodies against Sarbecoviruses including SARS-CoV-1 and the divergent SARS-CoV-2 subvariant KP.3.1.1

Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals

Potently neutralizing and protective human antibodies against SARS-CoV-2

SARS-CoV-2 Specific Nanobodies Neutralize Different Variants of Concern and Reduce Virus Load in the Brain of h-ACE2 Transgenic Mice

A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2

Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron

A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Two Pan-Sars-cov-2 Nanobodies and Their Multivalent Derivatives Effectively Prevent Omicron Infections in Mice.

Identification of a potent SARS-CoV-2 neutralizing nanobody targeting the receptor-binding domain of the spike protein

A Non-Ace2 Competing Human Single-Domain Antibody Confers Broad Neutralization Against SARS-CoV-2 and Circulating Variants.